Zhejiang Tianyu Pharmaceutical (300702.SZ) subsidiary has obtained approval for hydrochloride tablets of Vardenafil.

Zhejiang Tianyu Pharmaceutical (300702.SZ) announced that its wholly-owned subsidiary, Zhejiang Nuode Pharmaceutical Co., Ltd. (referred to as "Nuode Pharmaceutical"), recently received the Drug Registration Certificate for hydrochloride vardenafil tablets issued by the National Medical Products Administration. The indication is: treatment of male erectile dysfunction. With the approval of hydrochloride vardenafil tablets by the National Medical Products Administration, the company can produce and sell the product domestically, further enriching the variety and specifications of its formulations. This is expected to increase the company's formulation business revenue, enhance the market competitiveness of its products, and positively impact the companys operating performance.